42 results on '"Mandosi, Elisabetta"'
Search Results
2. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study
3. Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes
4. Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues
5. Endothelial dysfunction and oxidative stress in type 1 and type 2 diabetic patients without clinical macrovascular complications
6. Antioxidant Treatment Associated with Sildenafil Reduces Monocyte Activation and Markers of Endothelial Damage in Patients with Diabetic Erectile Dysfunction: A Double-Blind, Placebo-Controlled Study
7. Circulating Monocyte Oxidative Activity is Increased in Patients With Type 2 Diabetes and Erectile Dysfunction
8. Poor Glycemic Control Is an Independent Risk Factor for Low HDL Cholesterol in Patients With Type 2 Diabetes
9. Could gestational diabetes mellitus be managed through dietary bioactive compounds? Current knowledge and future perspectives
10. Un caso di ipotiroidismo associato a insufficienza renale reversibile e microematuria persistente
11. L’inibizione della GMP ciclico-fosfodiesterasi 5A migliora la cardiomiopatia diabetica: studio clinico randomizzato con risonanza magnetica
12. Uric acid levels in metabolic syndrome, type 2 diabetes and familial combined hyperlipidemia: a comparison
13. Patients with type 1 diabetes show a disappearance of the circadian rhythm of heart rate detected by ambulatori blood pressure monitoring
14. Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes
15. Effect of insulin on airway responsiveness in patients with type 2 diabetes mellitus: a cohort study
16. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkB levels and TNFalfa production in type 2 diabetes
17. Effetti Cardiovascolari della Somministrazione in Cronico di Sildenafil in Soggetti con ?Diabete Mellito di tipo 2
18. Cardiovascular effects of chronic sildenafil treatment in men with type 2 diabetes
19. Waist circumference reduction after insulin Detemir therapy in type 2 diabetes patients previously treated with NPH
20. Prevalenza di bassi livelli di colesterolo HDL e correlazione con il grado di controllo glicometabolico in pazienti con diabete di tipo 2
21. Sindrome metabolica e disfunzione erettile in una popolazione di pazienti obesi non diabetici
22. Atorvastatin downregulates monocyte CD36 scavenger receptor expression and nuclear NFkB levels in type 2 diabetic patients
23. Effetti del trattamento con atorvastatina sull'espressione del CD36 e sui livelli di NFkB nucleare in monociti circolanti di pazienti con diabete di tipo 2
24. The metabolic sindrome is not a risk factor for reduced kidney function in obese non diabetic subjects
25. The metabolic syndrome and insulin resistance are not risk factors for chronic kidney disease in obese non diabetic subjects
26. Antioxidant treatment associated to sildenafil reduces monocyte activation an markers of endothelial damage in patients with diabetes and erectyle dysfunction
27. In pazienti diabetici l’escrezione urinaria di VEGF è correlata all’albuminuria
28. L’attività ossidante dei monociti circolanti è aumentata in pazienti con diabete di tipo 2 e disfunzione erettile
29. Identificazione e caratterizzazione di proteine poly(ADP-ribosil)ate in mononucleati circolanti di diabetici di tipo 2 mediante proteomica
30. La disfunzione erettile e i disturbi sessuali nel diabete
31. L’attivita’ ossidante dei monociti circolanti e’ aumentata in pazienti diabetici con disfunzione erettile
32. Aumentata espressione di poly-ADP ribosio polymerasi in mononucleati circolanti di pazienti con diabete di tipo 2
33. Nefropatia
34. Il VEGF è correlato al rimodellamento ventricolare sinistro, ma non alla funzione renale in pazienti con diabete di tipo 2 ed ipertensione arteriosa
35. VENTRICULAR REMODELING IN PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION: ROLE OF VEGF
36. Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues
37. Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy
38. Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes
39. Atorvastatin Downregulates Monocyte CD36 Expression, Nuclear NFκB and TNFα Levels in Type 2 Diabetes
40. Metabolic Syndrome Is not a Risk Factor for Kidney Dysfunction in Obese Non-diabetic Subjects
41. Poly(ADP‐ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients
42. Does intervention on glycemic control influence HDL cholesterol levels in type 2 diabetes? A pilot study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.